Beware, Wegovy -- Pfizer Is Working on a Competitor
Which company is the leader in the burgeoning weight loss drug market? A recent poll found that among the largest drugmakers, (NYSE: PFE) is the one Americans associate most with this therapeutic area.
That's a surprising finding: Pfizer does not have a single anti-obesity medicine on the market and clearly trails Novo Nordisk (NYSE: NVO), the company behind Wegovy, in this field. However, Pfizer is trying to catch up; it recently announced it would advance one of its leading weight loss candidates to pivotal studies.
Pfizer has several anti-obesity candidates in the pipeline. One of the most advanced is danuglipron, an oral GLP-1 medicine. Note that Wegovy, also a GLP-1 drug, is administered subcutaneously once a week. Pfizer is investigating danuglipron as a twice-daily and once-daily pill, as some patients will prefer an oral formulation over subcutaneous injections.
Source Fool.com
Pfizer Inc. Aktie
Klares Buy-Übergewicht bei der Pfizer Inc. Aktie mit 29 zu 4 Einschätzungen.
Das von der Community festgelegte Kursziel für Pfizer Inc. von 41 € impliziert eine deutliche Steigerung gegenüber dem aktuellen Kurs von 27.88 €.
